Total Payments
$988,075
2024 Payments
$1,522
Companies
31
Transactions
736
Medicare Patients
9,925
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$516,516 (52.3%)
Consulting$352,614 (35.7%)
Travel$76,831 (7.8%)
Food & Beverage$24,104 (2.4%)
Research$17,906 (1.8%)
Education$74.43 (0.0%)
Gifts$30.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $501,366 | 112 | 50.7% |
| Consulting Fee | $352,614 | 112 | 35.7% |
| Travel and Lodging | $76,831 | 184 | 7.8% |
| Food and Beverage | $24,104 | 313 | 2.4% |
| Unspecified | $17,906 | 4 | 1.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $11,650 | 7 | 1.2% |
| Honoraria | $3,500 | 2 | 0.4% |
| Education | $74.43 | 1 | 0.0% |
| Gift | $30.00 | 1 | 0.0% |
Payments by Type
General
$970,169
732 transactions
Research
$17,906
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $273,221 | 201 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $132,272 | 93 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $124,988 | 68 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $116,210 | 89 | $0 (2023) |
| Genentech, Inc. | $101,066 | 81 | $0 (2023) |
| F. Hoffmann-La Roche AG | $51,279 | 16 | $0 (2024) |
| Alcon Vision LLC | $39,273 | 51 | $0 (2023) |
| Novartis Pharma AG | $33,748 | 5 | $0 (2021) |
| Carl Zeiss Meditec, Inc. | $25,027 | 29 | $0 (2023) |
| EyePoint Pharmaceuticals US, Inc. | $23,800 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,522 | 8 | F. Hoffmann-La Roche AG ($865.00) |
| 2023 | $23,143 | 25 | Genentech, Inc. ($19,700) |
| 2022 | $347,570 | 221 | Apellis Pharmaceuticals, Inc. ($116,162) |
| 2021 | $198,771 | 111 | Genentech USA, Inc. ($59,480) |
| 2020 | $54,919 | 38 | Genentech USA, Inc. ($19,328) |
| 2019 | $214,791 | 174 | Novartis Pharmaceuticals Corporation ($98,129) |
| 2018 | $71,386 | 83 | Genentech USA, Inc. ($38,202) |
| 2017 | $75,975 | 76 | Genentech USA, Inc. ($58,039) |
All Payment Transactions
736 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: EYE CARE | ||||||
| 11/19/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $36.00 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $136.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/28/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $865.00 | Research |
| Study: VA2 PhIII | ||||||
| 04/06/2024 | Carl Zeiss Meditec USA, Inc. | IOLMaster 700 (Device), MEL 90, VisuMax | Food and Beverage | In-kind items and services | $130.84 | General |
| Category: Optical Biometer | ||||||
| 04/06/2024 | Alcon Research LLC | AcrySof IQ VIVITY (Device) | Food and Beverage | In-kind items and services | $91.25 | General |
| Category: Ophthalmology | ||||||
| 03/28/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $127.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,083.50 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 12/15/2023 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $150.74 | General |
| Category: Ophthalmology | ||||||
| 11/21/2023 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $651.00 | General |
| Category: Ophthalmology | ||||||
| 09/19/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: EYE CARE | ||||||
| 09/18/2023 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $166.91 | General |
| Category: Ophthalmology | ||||||
| 09/11/2023 | Alimera Sciences, Inc. | YUTIQ (Drug) | Food and Beverage | Cash or cash equivalent | $22.64 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/31/2023 | Alcon Vision LLC | ARGOS (Device) | Food and Beverage | In-kind items and services | $115.03 | General |
| Category: Ophthalmology | ||||||
| 07/13/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $139.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/17/2023 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $98.65 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 05/16/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.15 | General |
| 05/09/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/21/2023 | Apellis Pharmaceuticals, Inc. | SYFOVRE (Drug) | Food and Beverage | Cash or cash equivalent | $24.85 | General |
| Category: Ophthalmology | ||||||
| 03/21/2023 | Apellis Pharmaceuticals, Inc. | SYFOVRE (Drug) | Food and Beverage | Cash or cash equivalent | $23.96 | General |
| Category: Ophthalmology | ||||||
| 02/28/2023 | Alcon Vision LLC | NGENUITY (Device) | Food and Beverage | In-kind items and services | $146.05 | General |
| Category: Ophthalmology | ||||||
| 02/27/2023 | Alcon Vision LLC | NGENUITY (Device) | Food and Beverage | In-kind items and services | $94.02 | General |
| Category: Ophthalmology | ||||||
| 02/17/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $785.00 | General |
| 02/16/2023 | Genentech, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DRUSEN CHARACTERISTICS AND DEVELOPMENT OF ADVANCED AGE-RELATED MACULAR DEGENERATION IN FELLOW EYES FROM THE HARBOR STUDY | F. Hoffmann-La Roche AG | $12,655 | 1 |
| Lucentis Dosing Retreatment | F. Hoffmann-La Roche AG | $3,303 | 1 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $1,084 | 1 |
| VA2 PhIII | F. Hoffmann-La Roche AG | $865.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,408 | 5,830 | $1.5M | $486,101 |
| 2022 | 19 | 3,052 | 7,151 | $2.8M | $933,063 |
| 2021 | 16 | 2,912 | 7,073 | $3.4M | $1.2M |
| 2020 | 16 | 2,553 | 6,499 | $3.3M | $1.2M |
Total Patients
9,925
Total Services
26,553
Medicare Billing
$3.8M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 70 | 388 | $647,242 | $262,742 | 40.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 20 | 3,181 | $236,643 | $90,258 | 38.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 121 | 336 | $126,562 | $33,615 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 215 | 320 | $87,364 | $22,323 | 25.6% |
| 92134 | Imaging of retina | Office | 2023 | 315 | 602 | $81,221 | $19,742 | 24.3% |
| 67028 | Injection of drug into eye | Facility | 2023 | 41 | 134 | $56,499 | $10,982 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 112 | $44,173 | $10,836 | 24.5% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 90 | 128 | $35,606 | $9,179 | 25.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 48 | 51 | $19,728 | $5,036 | 25.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 39 | 86 | $12,503 | $4,579 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 56 | 83 | $22,349 | $4,083 | 18.3% |
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 57 | 65 | $24,847 | $3,777 | 15.2% |
| 92134 | Imaging of retina | Facility | 2023 | 106 | 199 | $24,600 | $3,672 | 14.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 30 | $11,432 | $2,028 | 17.7% |
| 92012 | Established patient problem focused exam of visual system | Facility | 2023 | 27 | 37 | $10,071 | $1,474 | 14.6% |
| 92250 | Photography of the retina | Office | 2023 | 36 | 44 | $8,768 | $1,252 | 14.3% |
| 92250 | Photography of the retina | Facility | 2023 | 30 | 34 | $5,008 | $522.87 | 10.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 104 | 697 | $904,800 | $469,594 | 51.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 169 | 673 | $245,832 | $69,378 | 28.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 30 | 275 | $253,259 | $64,125 | 25.3% |
| 92134 | Imaging of retina | Office | 2022 | 597 | 1,328 | $180,474 | $45,129 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 278 | 309 | $120,922 | $32,644 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 268 | 395 | $105,695 | $29,229 | 27.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 20 | 977 | $128,432 | $29,155 | 22.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 186 | 386 | $108,783 | $27,646 | 25.4% |
About Dr. Caroline Baumal, MD
Dr. Caroline Baumal, MD is a Specialist healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891759106.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Caroline Baumal, MD has received a total of $988,075 in payments from pharmaceutical and medical device companies, with $1,522 received in 2024. These payments were reported across 736 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($501,366).
As a Medicare-enrolled provider, Baumal has provided services to 9,925 Medicare beneficiaries, totaling 26,553 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Uveitis and Ocular Inflammatory Disease
- Location Boston, MA
- Active Since 04/13/2006
- Last Updated 07/02/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1891759106
Products in Payments
- Lucentis (Biological) $212,512
- EYLEA (Biological) $132,162
- BEOVU (Drug) $91,378
- VABYSMO (Drug) $70,991
- Constellation (Device) $26,280
- YUTIQ (Drug) $23,605
- Non-Covered Product (Drug) $22,821
- Vabysmo (Drug) $19,216
- OZURDEX (Drug) $16,513
- Jetrea (Drug) $13,750
- EVA, combined machine (Device) $10,512
- CIRRUS HD-OCT (Device) $10,383
- ARGOS (Device) $6,415
- CIRRUS 6000 (Device) $4,550
- CLARUS 500 (Device) $4,550
- ILEVRO (Drug) $4,067
- XIPERE (Drug) $3,413
- CIRRUS 5000 with AngioPlex (Device) $2,600
- NGENUITY (Device) $2,271
- FORUM (Device) $2,216
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Boston
Keith Flaherty, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M
Dr. Paul Zei, M.d., Ph.d, M.D., PH.D
Specialist — Payments: $768,186
Specialist $768,186
Dr. Aman Patel, M.d, M.D
Specialist — Payments: $712,473
Specialist $712,473
Dr. Steven Treon, Md, Phd, MD, PHD
Specialist — Payments: $464,440
Specialist $464,440
Dr. Adam Rogers, M.d, M.D
Specialist — Payments: $316,568
Specialist $316,568
Xiuning Le, M.d, M.D
Specialist — Payments: $291,571
Specialist $291,571